Targeted Therapies Improve Outcomes in Renal Cancer and GIST, but Challenges Remain
Targeted therapies have significantly changed the treatment of cancer and are now considered to be a component of care for a number of common malignancies, including breast, colorectal, and lung cancers. In particular, they have significantly improved outcomes for patients with metastatic renal cell carcinoma (mRCC) and advanced gastrointestinal stromal tumors (GIST).
